MedTrace Logo

SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer

NCT05160896 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2023-06-08

No results posted yet for this study

Summary

The objective is to investigate the efficacy and safety of raltitrexed combined with Irinotecan (SALIRI) based regimen as first-line treatment for advanced metastatic colorectal cancer(mCRC).

Conditions

  • Advanced Metastatic Colorectal Cancer

Interventions

DRUG

Raltitrexed

Raltitrexed 2 mg/m² iv, 15min. day 1

DRUG

Irinotecan

Irinotecan 180 mg/m² iv, 30 - 90 min. day 1

DRUG

Bevacizumab

Bevacizumab 5 mg/kg, iv, day 1

DRUG

Cetuximab

cetuximab 500 mg/ m² , iv, day 1

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Ying Yuan, Ph.D&MD · Second Affiliated Hospital, School of Medicine, Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-12
Primary Completion
2023-06-30
Completion
2023-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05160896 on ClinicalTrials.gov